These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

227 related articles for article (PubMed ID: 21969523)

  • 1. Prevalence and characteristics of the metabolic syndrome in 2479 hypopituitary patients with adult-onset GH deficiency before GH replacement: a KIMS analysis.
    Verhelst J; Mattsson AF; Luger A; Thunander M; Góth MI; Koltowska-Häggström M; Abs R
    Eur J Endocrinol; 2011 Dec; 165(6):881-9. PubMed ID: 21969523
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prevalence of metabolic syndrome in adult hypopituitary growth hormone (GH)-deficient patients before and after GH replacement.
    Attanasio AF; Mo D; Erfurth EM; Tan M; Ho KY; Kleinberg D; Zimmermann AG; Chanson P;
    J Clin Endocrinol Metab; 2010 Jan; 95(1):74-81. PubMed ID: 19897679
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Isolated growth hormone (GH) deficiency in adult patients: baseline clinical characteristics and responses to GH replacement in comparison with hypopituitary patients. A sub-analysis of the KIMS database.
    Abs R; Mattsson AF; Bengtsson BA; Feldt-Rasmussen U; Góth MI; Koltowska-Häggström M; Monson JP; Verhelst J; Wilton P;
    Growth Horm IGF Res; 2005 Oct; 15(5):349-59. PubMed ID: 16168692
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Aspects of growth hormone deficiency and replacement in elderly hypopituitary adults.
    Feldt-Rasmussen U; Wilton P; Jonsson P; ;
    Growth Horm IGF Res; 2004 Jun; 14 Suppl A():S51-8. PubMed ID: 15135778
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Serum insulin-like growth factor I (IGF-I), IGF-binding proteins 2 and 3, and the risk for development of malignancies in adults with growth hormone (GH) deficiency treated with GH: data from KIMS (Pfizer International Metabolic Database).
    Popovic V; Mattsson AF; Gaillard RC; Wilton P; Koltowska-Häggström M; Ranke MB
    J Clin Endocrinol Metab; 2010 Sep; 95(9):4449-54. PubMed ID: 20610598
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Determinants of cardiovascular risk in 2589 hypopituitary GH-deficient adults - a KIMS database analysis.
    Abs R; Feldt-Rasmussen U; Mattsson AF; Monson JP; Bengtsson BA; Góth MI; Wilton P; Koltowska-Häggström M
    Eur J Endocrinol; 2006 Jul; 155(1):79-90. PubMed ID: 16793953
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Sheehan's syndrome: baseline characteristics and effect of 2 years of growth hormone replacement therapy in 91 patients in KIMS - Pfizer International Metabolic Database.
    Kelestimur F; Jonsson P; Molvalilar S; Gomez JM; Auernhammer CJ; Colak R; Koltowska-Häggström M; Goth MI
    Eur J Endocrinol; 2005 Apr; 152(4):581-7. PubMed ID: 15817914
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Metabolic syndrome and its components in adult hypopituitary patients.
    Abe SY; Dos Santos KS; Barbosa BFB; Biondo CMP; Takito D; Hayashi SK; Amarilla VGV; Ulbrich AZ; Boguszewski CL
    Pituitary; 2020 Aug; 23(4):409-416. PubMed ID: 32418172
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The reliability of the National Cholesterol Education Program's Adult Treatment Panel III (NCEP/ATP III) and the International Diabetes Federation (IDF) definitions in diagnosing metabolic syndrome (MetS) among Gaza Strip Palestinians.
    Sirdah MM; Abu Ghali AS; Al Laham NA
    Diabetes Metab Syndr; 2012; 6(1):4-8. PubMed ID: 23014247
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prevalence of diabetes mellitus in 6050 hypopituitary patients with adult-onset GH deficiency before GH replacement: a KIMS analysis.
    Abs R; Mattsson AF; Thunander M; Verhelst J; Góth MI; Wilton P; Kołtowska-Häggström M; Luger A
    Eur J Endocrinol; 2013 Mar; 168(3):297-305. PubMed ID: 23211573
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The prevalence of the metabolic syndrome and associated cardiovascular complications in adult-onset GHD during GH replacement: a KIMS analysis.
    Verhelst J; Mattsson AF; Camacho-Hübner C; Luger A; Abs R
    Endocr Connect; 2018 May; 7(5):653-662. PubMed ID: 29661785
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effects of long-term growth hormone replacement in adults with growth hormone deficiency following cure of acromegaly: a KIMS analysis.
    Tritos NA; Johannsson G; Korbonits M; Miller KK; Feldt-Rasmussen U; Yuen KC; King D; Mattsson AF; Jonsson PJ; Koltowska-Haggstrom M; Klibanski A; Biller BM
    J Clin Endocrinol Metab; 2014 Jun; 99(6):2018-29. PubMed ID: 24694339
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Abnormal metabolic phenotype in middle-aged GH-deficient adults despite long-term recombinant human GH replacement.
    Claessen KM; Appelman-Dijkstra NM; Pereira AM; Joustra SD; de Mutsert R; Gast KB; den Heijer M; Smit JW; Dekkers OM; Biermasz NR
    Eur J Endocrinol; 2014 Feb; 170(2):263-72. PubMed ID: 24217935
    [TBL] [Abstract][Full Text] [Related]  

  • 14. GH replacement in 1034 growth hormone deficient hypopituitary adults: demographic and clinical characteristics, dosing and safety.
    Abs R; Bengtsson BA; Hernberg-Stâhl E; Monson JP; Tauber JP; Wilton P; Wüster C
    Clin Endocrinol (Oxf); 1999 Jun; 50(6):703-13. PubMed ID: 10468941
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Nonfatal stroke, cardiac disease, and diabetes mellitus in hypopituitary patients on hormone replacement including growth hormone.
    Holmer H; Svensson J; Rylander L; Johannsson G; Rosén T; Bengtsson BA; Thorén M; Höybye C; Degerblad M; Bramnert M; Hägg E; Edén Engström B; Ekman B; Norrving B; Hagmar L; Erfurth EM
    J Clin Endocrinol Metab; 2007 Sep; 92(9):3560-7. PubMed ID: 17623762
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Analysis of characteristics and outcomes by growth hormone treatment duration in adult patients in the Italian cohort of the Hypopituitary Control and Complications Study (HypoCCS).
    Rochira V; Mossetto G; Jia N; Cannavo S; Beck-Peccoz P; Aimaretti G; Ambrosio MR; Di Somma C; Losa M; Ferone D; Lubrano C; Scaroni C; Giampietro A; Corsello SM; Poggi M
    J Endocrinol Invest; 2018 Nov; 41(11):1259-1266. PubMed ID: 29536433
    [TBL] [Abstract][Full Text] [Related]  

  • 17. GH deficiency after traumatic brain injury: improvement in quality of life with GH therapy: analysis of the KIMS database.
    Gardner CJ; Mattsson AF; Daousi C; Korbonits M; Koltowska-Haggstrom M; Cuthbertson DJ
    Eur J Endocrinol; 2015 Apr; 172(4):371-81. PubMed ID: 25583905
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The benefit of long-term growth hormone (GH) replacement therapy in hypopituitary adults with GH deficiency: results of the German KIMS database.
    Spielhagen C; Schwahn C; Möller K; Friedrich N; Kohlmann T; Moock J; Kołtowska-Häggström M; Nauck M; Buchfelder M; Wallaschofski H
    Growth Horm IGF Res; 2011 Feb; 21(1):1-10. PubMed ID: 21093334
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cardiovascular risk factors in hypopituitary GH-deficient adults.
    Verhelst J; Abs R
    Eur J Endocrinol; 2009 Nov; 161 Suppl 1():S41-9. PubMed ID: 19684057
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The effects of treatment and the individual responsiveness to growth hormone (GH) replacement therapy in 665 GH-deficient adults. KIMS Study Group and the KIMS International Board.
    Bengtsson BA; Abs R; Bennmarker H; Monson JP; Feldt-Rasmussen U; Hernberg-Stahl E; Westberg B; Wilton P; Wüster C
    J Clin Endocrinol Metab; 1999 Nov; 84(11):3929-35. PubMed ID: 10566630
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.